[Form 4] Q32 Bio Inc. Insider Trading Activity

Rhea-AI Filing Summary

Q32 Bio Inc. (QTTB) Chief Scientific Officer Shelia M. Violette reported the sale of 2,990 shares of common stock on 08/26/2025 with a weighted average price of $1.801 per share. The filing states the sales were automatic to satisfy tax withholding obligations related to the vesting of restricted stock units and were not at the reporting person’s discretion. After the transaction, Ms. Violette directly beneficially owns 58,384 shares and indirectly holds 36,277 shares through Violette Holdings LLC, of which she is a manager and disclaims beneficial ownership except for any pecuniary interest.

Insights

Financial Analyst

TL;DR: Routine tax-withholding sale of vested RSUs; minimal immediate market impact and no directional signal on company fundamentals.

The Form 4 documents an automatic disposition of 2,990 shares at a reported weighted average price of $1.801 to cover tax obligations from RSU vesting. Such transactions are common when restricted awards vest and are generally not driven by trading intent. The remaining direct and indirect holdings (58,384 and 36,277 shares) maintain the officer’s exposure, and the disclosure includes the manager/disclaimer language for Violette Holdings LLC. Overall, this is a routine insider administrative sale rather than an operational or governance event.

Corporate Governance Expert

TL;DR: Filing shows standard compliance with Section 16 reporting and appropriate disclosure of indirect holdings.

The report provides timely disclosure of an automatic sale tied to RSU tax withholding and clarifies the reporting person’s status as manager of Violette Holdings LLC while disclaiming beneficial ownership except for pecuniary interest. The form is signed by an attorney-in-fact, indicating procedural handling of the filing. No departures from standard reporting practice are evident in the document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Violette Shelia M.

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2025	08/27/2025	S(1)		2,990	D	$1.801(2)	58,384	D
Common Stock								36,277	I	By Violette Holdings LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

2. The price reported is a weighted average price. The securities were sold in multiple transactions over two consecutive trading days, at per share prices ranging from $1.81 to $1.96 and $1.73 to $1.83, respectively. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 2.

3. Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

	/s/ Eric Bell, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Q32 Bio (QTTB) insider Shelia Violette do on 08/26/2025?

The filing shows an automatic sale of 2,990 shares on 08/26/2025 to cover tax withholding related to vested RSUs.

At what price were the shares sold in the Form 4?

The reported weighted average sale price was $1.801 per share, with individual trades ranging between $1.73 and $1.96.

How many shares does Shelia Violette own after the transaction?

The report states 58,384 shares directly beneficially owned and 36,277 shares held indirectly by Violette Holdings LLC.

Why were the shares sold according to the filing?

The sales were automatic and occurred to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Does the filing indicate any change in control or material event?

No. The Form 4 describes a routine tax-withholding sale and a disclaimer of beneficial ownership for shares held by Violette Holdings LLC; no material corporate events are reported.